WithdrawnNot Applicable

Biomarker for Krabbe Disease (BioKrabbe)

Stopped: Transition into BioMetabol

Egypt, Germany, India0Started 2018-08-20

Plain-language summary

Development of a new MS-based biomarker for the early and sensitive diagnosis of Krabbe Disease from blood

Who can participate

Age range1 Year

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

INCLUSION CRITERIA: * Informed consent will be obtained from the patient or the parents before any study related procedures. * Patients of both gender from one year old * The patient has a diagnosis of Krabbe Disease EXCLUSION CRITERIA: * No Informed consent from the patient or the parents before any study related procedures. * Patients younger than one year * The patient has no diagnosis of Krabbe Disease

What they're measuring

Development of a new MS-based biomarker for the early and sensitive diagnosis of Krabbe disease from plasma

Timeframe: 24 month

Trial details

NCT IDNCT01425489

SponsorCENTOGENE GmbH Rostock

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2021-02-28

View on ClinicalTrials.gov More Krabbe Disease trials